EchoStar Corporation Common Stock vs GSK plc — how do they compare? EchoStar Corporation Common Stock trades at $97.01 (market cap $27.15B), while GSK plc trades at $46.82 (market cap $91.88B). The key difference: GSK plc is far larger — about 3.4× EchoStar Corporation Common Stock's market cap, and GSK plc pays a 3.9% dividend while EchoStar Corporation Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold EchoStar Corporation Common Stock for 0 Days and GSK plc for 93 Days on average.
| ECHO | GSK | |
|---|---|---|
Market Cap | $27.15B | $91.88B |
Volume | 4,944,235 | 7,730,529 |
Sector | Media | Health |
52-Week High | $141.80 | $61.18 |
52-Week Low | $66.93 | $43.24 |
Typical Hold Time | 0 Days | 93 Days |
Enterprise Value | $44.21B | $111.88B |
Dividend Yield | — | 3.9% |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
GSK trades at $47.02, up 0.9% today, with a bearish technical signal but strong fundamentals. The company reported revenue of $32.67B in 2025 with a net income margin of 14.52% and has beaten EPS estimates for three consecutive quarters. Recent news highlights strategic oncology investments and a $750M deal for a cancer therapy, signaling growth initiatives.
The outlook is mixed: solid profitability and a reasonable P/E of 15.1 support value, but technical indicators show bearish pressure near key support at $46. Risks include patent expirations and competitive pressures, while analyst sentiment is cautious with 31% buy ratings. Upside depends on pipeline execution and cost savings.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
EchoStar provides satellite communications and connectivity services. Its businesses support broadband, enterprise, government, and consumer communications needs.
Read more on ECHO →In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Read more on GSK →